A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
-
BUSINESS Global Brands Clinch Targeted Sales despite COVID-19, Drive Japan Makers in FY2020
June 21, 2021
-
REGULATORY Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
June 21, 2021
-
REGULATORY MHLW Aims to Set Up Evaluation Index, Sakigake System for SaMD by March
June 18, 2021
-
BUSINESS Merck’s COVID-19 Drug Candidate Enters PIII in Japan
June 18, 2021
-
BUSINESS Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
-
BUSINESS Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
-
REGULATORY Report Systems for Improper Drug Promotion Little-Known among Pharmacists: MHLW Study
June 16, 2021
-
REGULATORY Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
-
BUSINESS Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
-
BUSINESS Shipment Curbs of 3,000-Plus Products Taking a Toll on Wholesalers as Generic Woes Continue
June 15, 2021
-
ORGANIZATION Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
June 15, 2021
-
ORGANIZATION FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
June 14, 2021
-
BUSINESS Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
-
REGULATORY LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
-
BUSINESS Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
-
REGULATORY Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
-
BUSINESS Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
-
REGULATORY Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
-
BUSINESS Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…